<DOC>
	<DOC>NCT00411749</DOC>
	<brief_summary>The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females</brief_summary>
	<brief_title>V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Virginal Female Subject Aged 9 To 17 Years Male Subject</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>